Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV

Emanuela Marcantoni, PhD; Michael S. Garshick, MD, MS; Tamar Schwartz, BA; Nicole Ratnapala, MS; Matthew Cambria, BA; Rebecca Dann, MS; Meagan O’Brien, MD; Adriana Heguy, PhD; Jeffrey S. Berger, MD, MS

JACC: Basic to Translational Science (Nov 2022)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV

Emanuela Marcantoni, PhD,
Michael S. Garshick, MD, MS,
Tamar Schwartz, BA,
Nicole Ratnapala, MS,
Matthew Cambria, BA,
Rebecca Dann, MS,
Meagan O’Brien, MD,
Adriana Heguy, PhD,
Jeffrey S. Berger, MD, MS

Affiliations

Emanuela Marcantoni, PhD: Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
Michael S. Garshick, MD, MS: Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA; Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA
Tamar Schwartz, BA: Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
Nicole Ratnapala, MS: Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA
Matthew Cambria, BA: Division of Vascular and Endovascular Surgery, Department of Surgery, New York University School of Medicine, New York, New York, USA
Rebecca Dann, MS: New York Medical College, Valhalla, New York, USA
Meagan O’Brien, MD: Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA
Adriana Heguy, PhD: Genome Technology Center, New York University School of Medicine, New York, New York, USA
Jeffrey S. Berger, MD, MS: Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA; Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA; Division of Hematology, Department of Medicine, New York University School of Medicine, New York, New York, USA; Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, New York, USA; Address for correspondence: Dr Jeffrey S. Berger, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, 435 East 30th Street, 7th Floor, New York, New York 10016, USA.

Journal volume & issue: Vol. 7, no. 11
pp. 1086 – 1097

Abstract

Read online

Summary: Patients with HIV exhibit platelet activation and increased risk of cardiovascular disease, the prevention of which is not fully known. Fifty-five HIV-positive patients were randomized to clopidogrel, aspirin, or no-treatment for 14 days, and the platelet phenotype and ability to induce endothelial inflammation assessed. Clopidogrel as opposed to aspirin and no-treatment reduced platelet activation (P-selectin and PAC-1 expression). Compared with baseline, platelet-induced proinflammatory transcript expression of cultured endothelial cells were reduced in those assigned to clopidogrel, with no change in the aspirin and no-treatment arms. In HIV, clinical trials of clopidogrel to prevent cardiovascular disease are warranted. (Antiplatelet Therapy in HIV; NCT02559414)

Published in JACC: Basic to Translational Science

ISSN: 2452-302X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-basic-to-translational-science/

About the journal

Abstract

Keywords